文献速递白血病

Hedgehog通路突变驱动高危T细胞急性淋巴细胞白血病的致癌转化

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2018-03-20

研究探讨Hedgehog通路突变是否驱动T-ALL转化。在109例儿童T-ALL中16%存在Hedgehog通路突变,最常见为PTCH1负调控因子突变,与诱导化疗耐药相关(P=0.009)。斑马鱼模型显示ptch1突变加速notch1诱导的T-ALL发生(P=0.0001),药物抑制Hedgehog通路具有治疗活性。

要点

  • 109例儿童T-ALL中16%存在Hedgehog通路突变,最常见为PTCH1突变。
  • Hedgehog突变与诱导化疗耐药相关(P=0.009)。
  • 斑马鱼模型中ptch1突变加速notch1诱导的T-ALL发生(P=0.0001),药物抑制Hedgehog通路有治疗活性。

核心结论

  • Hedgehog通路激活突变是高危T-ALL的驱动性致癌改变,为该病靶向治疗提供了分子依据。

研究设计与样本

  • 研究纳入109例儿童T-ALL病例进行突变分析,并在斑马鱼模型中用CRISPR/Cas9系统进行谱系限制性基因敲除。

主要发现

  • 在109例儿童T-ALL中16%存在Hedgehog通路突变,最常见影响其负调控因子PTCH1。
  • Hedgehog突变与诱导化疗耐药相关(P=0.009)。
  • 将野生型PTCH1转导至PTCH1突变T-ALL细胞诱导凋亡(P=0.005),该表型可被下游Hedgehog通路激活逆转(P=0.007)。
  • 将多数突变型PTCH1、SUFU和GLI等位基因转导至哺乳动物细胞引起Hedgehog信号异常调控,提示这些突变为致病性。
  • 斑马鱼中ptch1突变加速notch1诱导的T-ALL发生(P=0.0001),药物抑制Hedgehog通路具有治疗活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of Hedgehog signaling in normal and malignant T-cell development is controversial. Recently, Hedgehog pathway mutations have been described in T-ALL, but whether mutational activation of Hedgehog signaling drives T-cell transformation is unknown, hindering the rationale for therapeutic intervention. Here, we show that Hedgehog pathway mutations predict chemotherapy resistance in human T-ALL, and drive oncogenic transformation in a zebrafish model of the disease. We found Hedgehog pathway mutations in 16% of 109 childhood T-ALL cases, most commonly affecting its negative regulator PTCH1. Hedgehog mutations were associated with resistance to induction chemotherapy (P = 0.009). Transduction of wild-type PTCH1 into PTCH1-mutant T-ALL cells induced apoptosis (P = 0.005), a phenotype that was reversed by downstream Hedgehog pathway activation (P = 0.007). Transduction of most mutant PTCH1, SUFU, and GLI alleles into mammalian cells induced aberrant regulation of Hedgehog signaling, indicating that these mutations are pathogenic. Using a CRISPR/Cas9 system for lineage-restricted gene disruption in transgenic zebrafish, we found that ptch1 mutations accelerated the onset of notch1-induced T-ALL (P = 0.0001), and pharmacologic Hedgehog pathway inhibition had therapeutic activity. Thus, Hedgehog-activating mutations are driver oncogenic alterations in high-risk T-ALL, providing a molecular rationale for targeted therapy in this disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Burns MA, Liao ZW, Yamagata N, et al. Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2018. PMID: 29654263. doi:10.1038/s41375-018-0097-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。